Botanix Pharmaceuticals announced the engagement of Michael Thurn as Chief Operating Officer. Thurn has unique experience in drug development, having recently led development of a topical treatment for acne being developed by venture capital backed company Mimetica. As CEO of Mimetica, Thurn successfully guided a melancortin-5 receptor targeting drug from pre-clinical testing through completion of a Phase 2 clinical trial.